Navigation Links
ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
Date:10/25/2012

SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today provided details regarding the phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease that it plans to initiate this quarter.  The Company will host a conference call today at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time (access information below) to discuss the study. 

The study will be a randomized, double-blind, two-arm, placebo-controlled study conducted at approximately 40 sites primarily in the U.S.  The primary objective will be to demonstrate that ANX-188 reduces the duration of vaso-occlusive crisis in patients with sickle cell disease.  The duration of vaso-occlusive crisis will be measured from the time a subject is randomized to the time at which the subject receives the last dose of parenteral opioid analgesic for the treatment of vaso-occlusive crisis prior to hospital discharge.  A total of 388 subjects ages 8 to 17 who have sickle cell disease and are experiencing acute pain typical of vaso-occlusive crisis will be enrolled.  Using a two-sided alpha of 0.05, the study has approximately 90% power to detect a 16-hour difference between treatment arms.  Secondary endpoints will compare re-hospitalization rate (for vaso-occlusive crisis) within 14 days of initial discharge from the hospital and the occurrence of acute chest syndrome within 120 hours of randomization. 

"Following an iterative and collaborative dialog with the FDA, and with valuable input from physicians who treat sickle cell patients, we are pleased to have finalized our phase 3 study protocol.  Consistent with our plans when we acquired ANX-188, the study will focus on children.  In a post-hoc analysis of a prior phase 3 study, ANX-188 demonstrated a statistically significant reduction in the duration of crisis in a subgroup of younger patients.  With the improvements we have incorporated into
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
2. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
3. ADVENTRX Announces Appointment Of Chief Medical Officer
4. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
5. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
6. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
7. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
8. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
9. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
10. Rochester Medical Announces Fourth Quarter 2012 Earnings Conference Call Tuesday, November 13, 2012
11. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Tianyin Pharmaceutical Co., Inc. ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today updates the timeline for the ... The Company is scheduled to ... China Food & Drug Administration,s (CFDA) review in ...
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that the market ... $7.7 billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s ... out by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2
... BEIJING, March 1, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... or the "Company"), an emerging leader in the ... and homecare medical products in China, today announced ... community conferences in March: (Logo: ...
... Diagnostics, Inc. announced today that the WARFARIN Study ( W ... or A dults R eceiving Genetic Testing at ... nationwide to assess the utility of genetic testing to determine ... risk of serious bleeding or clotting events. Warfarin, the most ...
Cached Medicine Technology:Dehaier Medical Announces March Investor Presentations 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3
(Date:8/28/2014)... 28, 2014 Gurnick Academy of Medical ... program is re-accredited for the 5 years of the ... Technologists (ARMRIT). , “We are very proud to ... our program to make sure we provide the best ... interest in MRI field nowadays and I look forward ...
(Date:8/28/2014)... A chronic problem in winemaking is "stuck fermentation," when ... alcohol and carbon dioxide prematurely shuts down, leaving the ... can spoil the wine. , A team of researchers ... a biochemical communication system behind this problem. Working ... can reproduce itself -- the system enables bacteria in ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
(Date:8/28/2014)... smoking kills approximately 440,000 Americans each year, according ... It,s the leading cause of preventable death worldwide. ... resort to nicotine replacement therapies. , A ... University of Miami (UM) suggest that small dosages ... harmful to human musculoskeletal system, due to overuse. ...
(Date:8/28/2014)... Lifesmart (formerly Source Network Sales and ... saunas, spas and hot tubs, today unveiled its entry ... purifiers, and price point multi-function tower fans. , “These ... established product lines and they will help us even ... less dependent on fourth quarter weather trends. Additionally ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:DeVincenzo study breakthrough in RSV research 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3Health News:Lifesmart Unveils New Line of Air Conditioners, Dehumidifiers, Humidifiers, Air Purifiers and Price Point Multi-Function Tower Fans Expanding the lifesmart zone Brand 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, April ... take calcium supplements to prevent bone deterioration may, in fact, be ... previous studies with similar findings, the new conclusions don,t necessarily mark ... study released online April 19 in the BMJ . ...
... at the University of Pennsylvania School of Medicine are delving ... of chromosomes. Recent work, e-published in Nature Structural & ... telomeres, can be protected by caps made up of specialized ... Telomere caps are like a knot at the end of ...
... major discovery about an enzyme,s structure has opened a window ... have determined the structure of a nuclease that will help ... for cancer research. DNA repair pathways are very important ... tools the cell uses to do those repairs are not ...
... that will test whether heart disease drugs can be used ... class of drugs - known as statins - can prevent ... cent of pregnant women in the UK. The ... research showing that statins, which are prescribed to lower heart ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- ... to curb misuse of extended-release and long-acting opioid pain killers ... Risk Evaluation and Mitigation Strategy (REMS) is part of a ... reduce overall prescription drug abuse in the United States. ...
... The European College of Neuropsychopharmacology (ECNP) is pleased ... the 2011 ECNP Neuropsychopharmacology Award in Basic Science ... the brain adenosine system. The ECNP Neuropsychopharmacology Award ... neuropsychopharmacology and closely related disciplines. The award is ...
Cached Medicine News:Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 2Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 3Health News:Ends of chromosomes protected by stacked, coiled DNA caps 2Health News:Ends of chromosomes protected by stacked, coiled DNA caps 3Health News:Nature's elegant solution to repairing DNA in cancer, other conditions 2Health News:Heart drugs could cut blood pressure risks in pregnancy 2Health News:FDA Looks to Crack Down on Misuse of Opioid Painkillers 2Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2
Stainless steel. Lamp is in fiberoptic handle. Green color coding. The blade includes a port that permits delivery of oxygen or other gas mixtures during intubation....
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Stainless steel. Lamp supplied with ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
Medicine Products: